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In this article the importance of blood proteins for drug dosing regimes is discussed.
A simple mathematical model is presented for estimating recommended drug doses
when the concentration of blood proteins is decreased. Practical guidance for drug
dosing regimes is discussed and given in the form of a figure. It is demonstrated
that correction of drug dosing regimes is needed only for when there is a high level
of drug conjugation with blood proteins and a high degree of hypoalbuminaemia.
An example of the use of this model is given.
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Blood proteins are transporters for most drugs. The free drug fraction has therapeutic
activity, but on the other hand it has potentially toxic side effects. Conjugation of a
drug with blood proteins is not constant and can be change in many clinical situations,
the most common of which is hypoalbuminaemia [1]. The concentrations of blood
proteins that bind drugs strongly has been shown to be important. When these con-
centrations change, clinicians need to adapt their dosing regimens rationally, on the
basis of the changed pharmacokinetic characteristics of the drug. For example, blood
proteins play critical roles in antibacterial drug dosing regimes for terminal patients
[2-5]. Among such patients, hypoalbuminaemia is very common, with reported inci-
dences as high as 40–50% [4,6].
It has been demonstrated that changes in protein binding can affect antiviral activity
and patient management. A change in protein binding causes a clinically important
change in the relationship between total and unconjugated concentrations of the drug.
Thus, blood proteins have critical effects on individual drug doses regimes and the effi-
cacy of antiviral therapy for HIV-infected patients [3,7-10].
Blood proteins also influence the penetration of drugs into tissues [11-13] and drug
elimination and metabolism [14,15]. Changes of free drug concentrations due to
hypoalbuminaemia can dramatically influence the therapeutic effects and induce side-
effects [16]. For example, proteins reduce the toxicity of anti-tumor drugs [17].
In obese patients, blood protein concentrations might be the main factor influencing
the drug dosing regimes [18,19]. The same mechanisms have been discussed for preg-
nancy [20,21] and for sex differences in drug dosing [22,23]. We previously demonstrated
critical changes of character in the kinetics of drug effects due to blood proteins [8,24,25].© 2013 Gurevich; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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protein concentrations are decreased are unclear. In this article we try to provide prac-
tical guidance for drug dosing in relation to blood protein concentration.
Results
As is well established, drugs in the blood can be found in both free and conjugates









From equation (1), the degree of drug conjugation (DC) can be calculated as:
DC ¼ free drug fraction
total drug in blood freeþ conjugated fractionsð Þ ⋅100% ð2Þ
The higher the DC, the less of the drug is free in the blood, and the lower its thera-peutic effect (the conjugated drug cannot interact with its molecular targets, i.e. recep-
tors; a conjugated drug is only a “reserve” of that drug).
The interaction of a drug with blood proteins determines its pharmacological activity
and its accumulation in tissues. Only the free fraction can penetrate into tissues from
the blood, and only the free fraction of the drug is extracted or metabolized [1,26]. A
scheme showing the influence of blood proteins on drug pharmacokinetics is given in
Figure 1.
Only a few drugs have specific blood-transport proteins; for most, the main binding
protein in the blood is albumin. Drug conjugation with blood proteins (i.e. albumin) is
determined by several factors [27]:
1. The chemical structure of the drug.
2. Possible interaction with blood proteins for several drugs or their metabolites.
3. Possible interactions with blood proteins for the drug and some endogenous
substances.
4. Total drug concentration in the blood. Because the capacity of proteins for a drug is
limited, it can be shown that for high drug concentrations, the DC decreases, i.e.
the amount of free drug increases (Figure 2a). In this situation the drug’s side
effects are more likely to be manifested.
5. Concentration of blood proteins. Increasing the concentration of blood proteins
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Figure 2 Concentration of conjugated drug fraction: influence of total drug concentration (a), and
influence of blood protein concentration (b).
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situation, correction of drug dosage is needed.
We offer a simple model estimation for the case of decreased blood protein concen-
tration (see below). From our point of view, the model results make clinical sense. The
model estimation for equation (13) is given in Figure 3. It is follows that for drugs with
high DC, the dosing regimes have to be altered when the blood protein concentration
is decreased. For drugs with low DC, this is not so important.
Therefore, in clinical practice, it is first necessary to measure the blood protein
concentrations as percentages of normal values. Then, from pharmacological databases,
the doctor should note the DC for the drug needed for the patient. For example, the
DC for cefixime is about 70% [4,5]. Using Figure 3, it can easily be found that when the
total blood protein concentration is 80% of normal, 88% of the usual dose of the drug
has to be used. When the blood protein concentration is 40% of normal, 58% of usualFigure 3 Recommended drug dosing regimes when blood protein concentration is decreased
(equation (13)). Numbers near lines are DC. To find the recommended dose, construct a perpendicular
from the X axis (point of blood protein concentration) until it intersects the line of DC for the current drug.
The Y axis value at this point gives the recommended drug dose.
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case but critical in the second.Discussion
Blood proteins play a critical role in the dosing regimes and side-effects of drugs
[4,5,16]. In cases of hypoalbuminaemia the profile of therapeutic safety of drugs
becomes lower, and probability that drug side-effects will develop is increased [1].
In this article we have demonstrated that the free fraction of the drug is dramatically
changed in hypoalbuminaemia only for drugs with high DC values, i.e. some antibacte-
rial and antiviral drugs. Because the free drug concentration directly influences the
drug’s therapeutic and side effects [16,17], dose regimes only have to be corrected for
drugs with high DC values in hypoalbuminaemia cases.
We present a simple model that allows the same concentration of free drug to be
attained in cases of both normal and decreased blood protein concentration. The
model gives practical guidance for drug dosing regimes in hypoalbuminaemia (Figure 3).
It is ready for clinical use and needs no additional calculations. Physicians need to
know only two things before using the model: the DC of the drug and the percentage
decrease of blood protein concentration below normal values. The first is given in drug
annotations, the second can be easily measured in a clinical laboratory.
For patients with bleeding, certain solutions (i.e. detraining) are used to restore the
blood volume. It has to be noted that such solutions contain no blood proteins. There-
fore, these patients require additional treatment with albumin or whole blood, or the
drug dosing regimens have to be changed.
It has to be remarked that our model has important limitations:
1. The results are true only for drugs with linear dependence of blood concentration
on intake dose. This seems valid for any intravenous or intramuscular drug intake.
But for oral intake, the blood drug concentration depends not on only on the dose
but also on food intake, drug solubility, gastric and intestinal pH, and numerous
other factors. However, hypoalbuminaemia usually means intensive care is needed,
so most drugs need to be given intravenously or intramuscularly.
2. The model takes no account of possible changes in the equilibrium constant, K.
These might correspond to blood pH changes, changes of blood temperature
(due to changes of total body temperature), genetic or chemical modifications of
blood proteins, or other factors.
3. The results are valid only for drugs binding to one type of blood protein
transporter (or several transporters with similar values of K). However, for
antimicrobial and antiviral drugs, this assumption is true, so our model seems to be
clinical relevant.Model estimation
Let us calculate safe drug dosing regimes when the blood protein concentration is
reduced. It has to be remarked that such a decrease in blood proteins is a common
clinical situation: it occurs in renal and liver diseases, bleeding and so on. From our
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drugs with high DC values.
In the simplest situation there is only one drug (L) and one type of blood protein (P).
Their interaction is reversible with equilibrium constant (K):
Lþ P↔K LP ð3Þ
where LP is the complex of drug with blood protein (i.e. conjugated drug).
Here, the equilibrium constant can be calculated as (square brackets are used to
denote concentrations of appropriate substances):
K ¼ L½ ⋅ P½ 
LP½  ð4Þ
and DC is:
DC ¼ LP½ 
L0½  ð5Þ
where [L0] is total drug concentration in the blood. Or:
LP½  ¼ DC L0½  ð6Þ
It is obvious that:
L0½  ¼ LP½  þ L½  ð7Þ
So, given (7), equation (4) can be rewritten as:K ¼ L0½  1 DCð Þ P½ 
DC L0½  ¼




DC ¼ P½ 
K þ P½  ð9Þ
If the blood protein concentration decreases а-fold, equation (9) can be rewritten as:DC1 ¼ a P½ K þ a P½  ð10Þ
where DC1 is the DC when the blood protein concentration is decreased.
From equations (6) and (9), the free drug concentration in normal blood is:
L½  ¼ L0½  1 DCð Þ
and when the blood protein concentration is decreased:
L1½  ¼ L01½  1 DC1ð Þ
where [L01] is the total drug concentration in such a case.
It can be assumed that when [L] = [L1] there will be no side effects corresponding to
the increased free drug fraction. I.e.:
L01½  1 DC1ð Þ ¼ L0½  1 DCð Þ ð11Þ
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Equation (13) allows changes in [L01] to be calculated and compared with [L0], with
the limitation [L] = [L1]. Graphically, the results of estimation are illustrated in Figure 3.
These calculations are valid when the blood concentration of the drug is a linear func-
tion of its dose.
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